Qol Holdings (3034) Q4 2026 earnings summary

Executive summary

• Achieved record-high consolidated sales, operating profit, ordinary profit, and profit attributable to owners of parent for FY3/2026, with all segments contributing to growth.

• Pharmacy business saw increased sales and technical fee unit price, but profit declined due to fee revisions, stricter requirements, higher labor costs, and longer prescription periods.

• BPO Contracting and Pharmaceutical Manufacturing businesses delivered higher sales and profit, driven by increased demand, new product launches, and increased ownership in DAIICHI SANKYO ESPHA.

Financial highlights

• Net sales rose 10.2% year-over-year to ¥290.8 billion; EBITDA up 12.8% to ¥24.6 billion.

• Operating profit increased 10.0% to ¥14.8 billion; ordinary profit up 7.6% to ¥14.9 billion; profit attributable to owners of parent surged 43.5% to ¥7.4 billion.

• Net income per share climbed 43.0% to ¥197.35; comprehensive income reached ¥8,485 million, up 13.4%.

• ROE improved to 12.9% from 9.4% in the prior year.

Outlook and guidance

• FY3/2027 targets: net sales ¥315 billion (+8.3%), operating profit ¥16.5 billion (+11.4%), ordinary profit ¥16.5 billion (+10.9%), profit attributable to owners of parent ¥7.8 billion (+5.3%), EBITDA ¥28.7 billion (+16.5%).

• Dividend per share expected to rise to ¥54; strategic focus on expanding all segments, leveraging DX, and pursuing sustainability and SDGs.

• Long-term vision targets ¥500 billion in net sales and ¥35 billion in operating profit by 2030.